In Focus: Blinatumomab for Non-Hodgkin Lymphoma – Cancer Therapy Advisor
Cancer Therapy Advisor |
In Focus: Blinatumomab for Non-Hodgkin Lymphoma
Cancer Therapy Advisor “BiTEs have an advantage over other T cell technologies, including chimeric antigen receptor T [CAR–T] cell programs in that they are ready right off the shelf for use, with no delay in initiating therapy,” Dr Barnes said. He noted that they have … |
